ULTRA (samfilcon A) Visibility Tinted Soft Contact Lenses
Bausch and Lomb, Inc., · Decision date Sep 15, 2025
What did the FDA decide?
FDA records P170035/S018 as a supplement to PMA P170035, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 15, 2025.
FDA approval order statement
implement concentration control tanks in manufacturing lines to reduce the IPA usage concentration at Bausch + Lombs manufacturing facility located in Rochester, NY
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 15, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P170035/S018
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch and Lomb, Inc.,
- Product code
- LPM
- Decision code
- OK30
- Decision date
- Sep 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Applicant
- Bausch and Lomb, Inc.,
- Product code
- LPM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170035. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170035 · Original PMA
Bausch + Lomb Ultra (samfilcon A) Contact Lenses
P170035/S018 received
Application receipt date recorded by FDA.
P170035/S018 · FDA decision
30-Day Notice
P170035/S019 · Related supplement
Bausch + Lomb Ultra (Samfilcon A) Visibly Tinted (Soft) Contact Lenses
P170035/S021 · Related supplement
Bausch + Lomb Ultra (samfilcon A) Contact Lenses
Timeline entries are records held by MedtechLedger for P170035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch and Lomb, Inc., | PMA approval | Apr 30, 2018 | FDA | |
| Bausch and Lomb, Inc., | PMA supplement | Dec 4, 2025 | FDA | |
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
| CooperVision, Inc. | PMA supplement | Jul 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch and Lomb, Inc.,
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14609
Sources and methodology
- Original FDA record: P170035/S018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



